MXPA03011455A - Complejo soluble que comprende glucoproteina de superficie retroviral. - Google Patents
Complejo soluble que comprende glucoproteina de superficie retroviral.Info
- Publication number
- MXPA03011455A MXPA03011455A MXPA03011455A MXPA03011455A MXPA03011455A MX PA03011455 A MXPA03011455 A MX PA03011455A MX PA03011455 A MXPA03011455 A MX PA03011455A MX PA03011455 A MXPA03011455 A MX PA03011455A MX PA03011455 A MXPA03011455 A MX PA03011455A
- Authority
- MX
- Mexico
- Prior art keywords
- hiv
- chaperone
- surface glycoprotein
- variant
- retroviral surface
- Prior art date
Links
- 230000001177 retroviral effect Effects 0.000 title abstract 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 title 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 title 1
- 208000031886 HIV Infections Diseases 0.000 abstract 3
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 abstract 2
- 101800000385 Transmembrane protein Proteins 0.000 abstract 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 abstract 1
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 abstract 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- -1 respectively Proteins 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01115225 | 2001-06-22 | ||
| EP01120939 | 2001-08-31 | ||
| PCT/EP2002/006956 WO2003000877A2 (en) | 2001-06-22 | 2002-06-24 | A soluble complex comprising a retroviral surface glycoprotein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03011455A true MXPA03011455A (es) | 2004-04-05 |
Family
ID=26076626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03011455A MXPA03011455A (es) | 2001-06-22 | 2002-06-24 | Complejo soluble que comprende glucoproteina de superficie retroviral. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7244819B2 (https=) |
| EP (3) | EP1402015B1 (https=) |
| JP (6) | JP4174422B2 (https=) |
| KR (2) | KR100702373B1 (https=) |
| CN (1) | CN100510068C (https=) |
| AT (2) | ATE445016T1 (https=) |
| AU (2) | AU2002317841A1 (https=) |
| BR (1) | BRPI0210598B8 (https=) |
| CA (3) | CA2449747C (https=) |
| DE (1) | DE60233942D1 (https=) |
| DK (2) | DK1402015T3 (https=) |
| ES (3) | ES2391623T3 (https=) |
| MX (1) | MXPA03011455A (https=) |
| PL (2) | PL218245B1 (https=) |
| WO (2) | WO2003000878A2 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1402015T3 (da) * | 2001-06-22 | 2011-12-05 | Hoffmann La Roche | Opløseligt kompleks omfattende et retroviralt overfladeglycoprotein og FkpA eller SlyD |
| CA2490384A1 (en) * | 2002-06-25 | 2003-12-31 | Sekisui Chemical Co., Ltd. | Expression vector, host, fused protein, process for producing fused protein and process for producing protein |
| WO2004047869A1 (en) * | 2002-11-26 | 2004-06-10 | Danmarks Fødevareforskning | Dendrimer conjugates for selective of protein aggregates |
| WO2004092221A1 (ja) * | 2003-04-18 | 2004-10-28 | Sekisui Chemical Co. Ltd. | 免疫原及び免疫用組成物、並びにそれらを使用する抗体の製造方法 |
| DK2330200T3 (en) * | 2004-12-23 | 2017-07-24 | Albumedix As | GENE EXPRESSION TECHNIQUE |
| CA2562738C (en) | 2005-10-26 | 2011-07-12 | F. Hoffmann-La Roche Ag | Soluble rubella e1 envelope antigens |
| CA2636075C (en) * | 2006-01-03 | 2011-11-08 | F. Hoffmann-La Roche Ag | Chimaeric fusion protein with superior chaperone and folding activities |
| WO2007141650A2 (en) * | 2006-01-17 | 2007-12-13 | Instituto De Medicina Molecular | Compositions and methods for diagnosing hiv-2 infection |
| US8962262B2 (en) | 2006-05-11 | 2015-02-24 | Arbor Vita Corporation | Method of protein extraction from cells |
| GB0611405D0 (en) | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
| PL2112158T3 (pl) | 2007-04-20 | 2012-03-30 | Hoffmann La Roche | Wykrywanie pierwotnych infekcji wywołanych patogenami |
| US20100210827A1 (en) * | 2007-09-06 | 2010-08-19 | Nutrex Technology Co., Ltd. | Preparation Method Of Recombinant Protein By Use Of A Fusion Expression Partner |
| US9207240B2 (en) | 2007-11-14 | 2015-12-08 | Arbor Vita Corporation | Method of efficient extraction of protein from cells |
| EP2222694B1 (en) | 2007-12-13 | 2014-01-15 | Roche Diagnostics GmbH | Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies |
| EP2127678A1 (en) | 2008-05-26 | 2009-12-02 | Roche Diagnostics GmbH | SlpA as a tool for recombinant protein and enzyme technology |
| EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| EP2670847B1 (en) * | 2011-02-03 | 2016-10-05 | XOMA Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| AR086250A1 (es) * | 2011-05-05 | 2013-11-27 | Hoffmann La Roche | Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| EP2617731A1 (en) | 2012-01-19 | 2013-07-24 | Roche Diagnostics GmbH | Soluble immunoreactive Treponema pallidum TpN47 antigens |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| EP2706115A1 (en) | 2012-09-06 | 2014-03-12 | Roche Diagnostics GmbH | Chaperone-chaperone fusion polypeptides for reduction of interference and stabilization of immunoassays |
| MX2015005757A (es) | 2012-11-08 | 2015-11-18 | Hoffmann La Roche | Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3. |
| US12540318B2 (en) * | 2012-11-08 | 2026-02-03 | Roche Diagnostics Operations, Inc. | Nucleic acids encoding chimeric polypeptides for library screening |
| US9725511B2 (en) | 2012-11-08 | 2017-08-08 | Hoffmann-La Roche Inc. | Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4 |
| EP2827146A1 (en) | 2013-07-18 | 2015-01-21 | Roche Diagnostics GmbH | Vibrio cholerae lipoprotein 15 (Lp15) variants as anti-interference additive in TpN17-based immunoassays for detection of anti-Treponema antibodies |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| EP3049437A1 (en) * | 2013-09-27 | 2016-08-03 | F. Hoffmann-La Roche AG | Thermus thermophilus slyd fkbp domain specific antibodies |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP2913338A1 (en) | 2014-02-28 | 2015-09-02 | Roche Diagniostics GmbH | Soluable and immunoreactive variants of HTLV capsid antigen p24 |
| JP2015215244A (ja) * | 2014-05-12 | 2015-12-03 | 富士レビオ株式会社 | 免疫測定における抗ｈｔｌｖ抗体の検出感度を向上させる方法 |
| MX2016014416A (es) | 2014-05-14 | 2017-02-23 | Hoffmann La Roche | Anticuerpos anti-her3 que se unen a la horquilla beta de her3. |
| MX2016014862A (es) * | 2014-05-14 | 2017-02-27 | Hoffmann La Roche | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. |
| JP6817939B2 (ja) * | 2014-12-01 | 2021-01-20 | フェネックス インク． | ペプチド産生のための融合パートナー |
| US20180023098A1 (en) * | 2015-02-13 | 2018-01-25 | Sekisui Chemical Co., Ltd. | Nucleic acid, fusion protein, recombined cell, and isoprene or cyclic terpene production method |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| KR102943992B1 (ko) * | 2015-12-15 | 2026-03-25 | 에프. 호프만-라 로슈 아게 | 트랜스글루타미나제 인식 부위를 갖는 fkbp 도메인 |
| JP7044721B2 (ja) | 2016-05-31 | 2022-03-30 | エフ．ホフマン－ラ ロシュ アーゲー | Ｈｃｖコア抗原の迅速な検出のための前処理法 |
| EP3465217B1 (en) | 2016-05-31 | 2025-09-03 | Roche Diagnostics GmbH | Method for serological detection of viral antigens |
| EP3472322B1 (en) * | 2016-06-20 | 2022-01-05 | MetGen Oy | Method for obtaining active insoluble xylose isomerase |
| WO2018141768A1 (en) | 2017-02-02 | 2018-08-09 | Roche Diagnostics Gmbh | Immunoassay using at least two pegylated analyte-specific binding agents |
| BR112019022384A2 (pt) | 2017-04-26 | 2020-05-26 | F. Hoffmann-La Roche Ag | Polipeptídeo apropriado para detecção de anticorpos contra vírus zika, métodos de produção de polipeptídeo, de detecção de anticorpos específicos para vírus zika e de detecção de anticorpos contra vírus zika, uso de polipeptídeo do vírus zika e kit de reagentes |
| ES2961462T3 (es) | 2017-07-27 | 2024-03-12 | Roche Diagnostics Gmbh | Proteína de fusión multiepítopo de un antígeno del VHC y usos de la misma |
| CN110066343B (zh) * | 2019-05-23 | 2021-04-09 | 北京新创生物工程有限公司 | 一种用于检测hiv新发感染的重组抗原及其应用 |
| CN115843334B (zh) | 2020-04-23 | 2026-01-13 | 豪夫迈·罗氏有限公司 | 用于抗体免疫测定的冠状核衣壳抗原 |
| EP4380955A1 (en) | 2021-08-06 | 2024-06-12 | Roche Diagnostics GmbH | Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification |
| WO2023213758A1 (en) | 2022-05-03 | 2023-11-09 | F. Hoffmann-La Roche Ag | Hiv gp41 variants for immunodiagnostic assays |
| WO2025098623A1 (en) | 2023-11-09 | 2025-05-15 | Roche Diagnostics Gmbh | Transglutaminase substrates for labeling |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2095818B (en) | 1981-03-27 | 1985-10-02 | Exxon Research Engineering Co | Staged adsorption/resorption heat pump |
| US4735896A (en) | 1986-03-04 | 1988-04-05 | United Biomedical, Inc. | Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions |
| US4879212A (en) | 1986-04-02 | 1989-11-07 | United Biomedical Inc. | Peptide composition and method for the detection of antibodies to HTLV-III |
| US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
| DE3705686C2 (de) | 1987-02-23 | 1995-11-30 | Boehringer Mannheim Gmbh | Verfahren zur Bestimmung von Antikörpern |
| NZ224663A (en) | 1987-05-28 | 1990-11-27 | Amrad Corp Ltd | Fusion proteins containing glutathione-s-transferase and expression of foreign polypeptides using glutathione-s-transferase encoding vectors |
| SE8704185L (sv) | 1987-10-28 | 1989-04-29 | Ferring Ab | Nya peptider, artificiella antigener och immunoanalystestsatser |
| CA2003383A1 (en) * | 1988-11-23 | 1990-05-23 | Sushil G. Devare | Synthetic dna derived recombinant hiv antigens |
| DE69223250T3 (de) | 1991-06-14 | 2008-02-28 | Idexx Laboratories, Inc. | Detektion des immunschwäche-virus aus felis |
| JPH07504561A (ja) * | 1991-12-20 | 1995-05-25 | ノボ ノルディスク アクティーゼルスカブ | リパーゼの製造のための方法 |
| EP0644950A4 (en) | 1992-04-09 | 1997-05-14 | Abbott Lab | ASSAY FOR THE DETECTION OF HIV ANTIGEN AND HIV ANTIBODIES. |
| AU4400593A (en) | 1992-06-05 | 1994-01-04 | Abbott Laboratories | Methods and reagents for the determination of immunosuppressive agents |
| EP0663010B1 (en) | 1992-10-02 | 2000-08-09 | Research Corporation Technologies, Inc. | Methods for increasing secretion of overexpressed proteins |
| US5459051A (en) | 1993-03-26 | 1995-10-17 | Celtrix Pharmaceuticals, Inc. | Methods and vectors for over-expression of ubiquitin fusion proteins in host cells |
| DE4428705A1 (de) * | 1994-08-12 | 1996-02-15 | Boehringer Mannheim Gmbh | Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus |
| JPH11511643A (ja) | 1994-10-25 | 1999-10-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニア・ユニバーシティ | 遺伝子工学処理された細胞の条件的形質転換 |
| KR19990022651A (ko) | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| EP0855029A4 (en) | 1995-09-15 | 2000-03-08 | Merck & Co Inc | An assay with high throughput using fusion protein |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| GB9614114D0 (en) | 1996-07-05 | 1996-09-04 | Amcor Packaging Uk Ltd | New packages |
| AU736670B2 (en) | 1996-09-26 | 2001-08-02 | Medical Research Council | Chaperone fragments |
| US6225082B1 (en) | 1997-05-09 | 2001-05-01 | Research Corporation Technologies, Inc. | Myelin basic protein MRNA transport and translation enhancer sequences |
| US5989868A (en) * | 1997-09-12 | 1999-11-23 | The Board Of Regents Of The University Of Oklahoma | Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli |
| CA2318402A1 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| DE19913117A1 (de) * | 1998-05-06 | 1999-11-11 | Roche Diagnostics Gmbh | Entstörung durch Rheumafaktoren |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| ATE473755T1 (de) * | 1998-10-02 | 2010-07-15 | Rhein Biotech Proz & Prod Gmbh | Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 large t antigen mit einem intakten n terminus |
| JP2002529081A (ja) | 1998-11-06 | 2002-09-10 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 生物学的事象のｆｋ５０６に基づく調節 |
| EP1161440A1 (en) | 1999-03-17 | 2001-12-12 | Medical Research Council | Method for refolding molecules of polypeptides containing ig domains |
| AU4933200A (en) | 1999-05-14 | 2000-12-05 | Medical Research Council | Oligomeric chaperone proteins |
| GB9913437D0 (en) | 1999-06-09 | 1999-08-11 | Medical Res Council | Fusion proteins |
| EP1077263A1 (de) * | 1999-07-29 | 2001-02-21 | F.Hoffmann-La Roche Ag | Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen |
| CA2403718A1 (en) | 2000-03-17 | 2001-09-27 | Panacos Pharmaceuticals, Inc. | A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins |
| JP2002262883A (ja) * | 2001-03-13 | 2002-09-17 | Sekisui Chem Co Ltd | モノクローナル抗体の製造方法 |
| DK1402015T3 (da) * | 2001-06-22 | 2011-12-05 | Hoffmann La Roche | Opløseligt kompleks omfattende et retroviralt overfladeglycoprotein og FkpA eller SlyD |
-
2002
- 2002-06-24 DK DK02758265.9T patent/DK1402015T3/da active
- 2002-06-24 CA CA2449747A patent/CA2449747C/en not_active Expired - Lifetime
- 2002-06-24 ES ES10173342T patent/ES2391623T3/es not_active Expired - Lifetime
- 2002-06-24 DE DE60233942T patent/DE60233942D1/de not_active Expired - Lifetime
- 2002-06-24 JP JP2003507263A patent/JP4174422B2/ja not_active Expired - Fee Related
- 2002-06-24 AT AT02747428T patent/ATE445016T1/de active
- 2002-06-24 EP EP02758265A patent/EP1402015B1/en not_active Expired - Lifetime
- 2002-06-24 JP JP2003507262A patent/JP4262594B2/ja not_active Expired - Fee Related
- 2002-06-24 WO PCT/EP2002/006957 patent/WO2003000878A2/en not_active Ceased
- 2002-06-24 ES ES02758265T patent/ES2372031T3/es not_active Expired - Lifetime
- 2002-06-24 MX MXPA03011455A patent/MXPA03011455A/es active IP Right Grant
- 2002-06-24 CA CA2450476A patent/CA2450476C/en not_active Expired - Lifetime
- 2002-06-24 AU AU2002317841A patent/AU2002317841A1/en not_active Abandoned
- 2002-06-24 EP EP02747428A patent/EP1402041B1/en not_active Expired - Lifetime
- 2002-06-24 AT AT02758265T patent/ATE522603T1/de active
- 2002-06-24 BR BR0210598-5 patent/BRPI0210598B8/pt not_active IP Right Cessation
- 2002-06-24 EP EP10173342A patent/EP2267452B8/en not_active Expired - Lifetime
- 2002-06-24 KR KR1020037016770A patent/KR100702373B1/ko not_active Expired - Fee Related
- 2002-06-24 KR KR1020067005314A patent/KR100611545B1/ko not_active Expired - Fee Related
- 2002-06-24 DK DK10173342.6T patent/DK2267452T3/da active
- 2002-06-24 CA CA2770453A patent/CA2770453C/en not_active Expired - Fee Related
- 2002-06-24 PL PL397776A patent/PL218245B1/pl unknown
- 2002-06-24 ES ES02747428T patent/ES2333108T3/es not_active Expired - Lifetime
- 2002-06-24 CN CNB028124715A patent/CN100510068C/zh not_active Expired - Lifetime
- 2002-06-24 AU AU2002325265A patent/AU2002325265B2/en not_active Expired
- 2002-06-24 WO PCT/EP2002/006956 patent/WO2003000877A2/en not_active Ceased
- 2002-06-24 US US10/179,038 patent/US7244819B2/en not_active Expired - Lifetime
- 2002-06-24 PL PL367679A patent/PL215170B1/pl unknown
-
2006
- 2006-12-04 JP JP2006326846A patent/JP4309910B2/ja not_active Expired - Fee Related
-
2007
- 2007-04-13 US US11/786,847 patent/US8426167B2/en not_active Expired - Fee Related
- 2007-07-12 JP JP2007183508A patent/JP4320351B2/ja not_active Expired - Fee Related
-
2008
- 2008-11-07 JP JP2008286959A patent/JP2009102320A/ja not_active Withdrawn
-
2009
- 2009-02-06 JP JP2009025509A patent/JP4523660B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03011455A (es) | Complejo soluble que comprende glucoproteina de superficie retroviral. | |
| DK1159298T3 (da) | HIV-peptider, antigener og vaccinekompositioner | |
| WO2002064615A3 (en) | Monoclonal antibodies to human immunodeficiency virus and uses thereof | |
| WO2002020554A3 (en) | Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines | |
| DE3855134D1 (de) | Monoklonale menschliche antikörper gegen hiv-i | |
| EP1016671A3 (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) | |
| KR100725637B1 (en) | Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein | |
| WO1997046697A3 (en) | Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections | |
| JP2002508338A5 (https=) | ||
| WO2003052122A3 (en) | Gp41 inhibitor | |
| ATE521640T1 (de) | Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen | |
| ATE509942T1 (de) | Nichtproteolysierbare oligopeptide, die das glycoprotein gp41 von hiv inhibieren | |
| WO2007018550A3 (en) | Compositions and methods for the detection of hiv-1/hiv-2 infection | |
| DK1368478T3 (da) | Polypeptid, der fremkalder HIV-neutraliserende antistoffer | |
| WO2002034909A3 (en) | Engineered chimera of hiv protein fragments and uses thereof | |
| RU2000106709A (ru) | Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5 | |
| WO2002059258A3 (en) | Chimeric proteins for prevention and treatment of hiv infection | |
| FR2874612A1 (fr) | Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications | |
| Shokunbi et al. | Incidence of antibodies to HIV₁ and HIV₂ gene products in seropositive cases seen in Ibadan, Nigeria | |
| ATE137801T1 (de) | Gegen hiv 1 gp48 spezifische antikörper | |
| ATE349532T1 (de) | Zytotoxisches t-zellepitop des papillomavirus l1- proteins und seine verwendung in diagnostik und therapie | |
| TH87273A (th) | วัคซีน | |
| TH62264A (th) | Hiv เพพไทด์, แอนติเจน องค์ประกอบวัคซีน, ชุดสำเร็จรูปอิมมูโนแอสเสย์ และวิธีสำหรับตรวจหาแอนติบอดีที่ชักนำโดย hiv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |